

# PRECEPTORSHIP PROGRAMME

## Immuno-Oncology

From the essentials of tumour  
immunology to clinical application

**SINGAPORE**

**20-21 NOVEMBER 2017**

Co-Chairs    John B.A.G. Haanen, NL  
                    Ross A. Soo, SG

# ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

**Singapore**  
**20-21 November 2017**

---

## CO-CHAIRS:

John B.A.G. Haanen, Netherlands  
Ross A. Soo, Singapore

## SPEAKERS:

Anthony Tak Cheung Chan, Hong Kong  
Su Pin Choo, Singapore  
Teh-Ying Chou, Taiwan  
Ravindran Kanesvaran, Singapore  
Soon Thye Lim, Singapore  
Kenneth John O'Byrne, Australia

Solange Peters, Switzerland  
Matthias Preusser, Austria  
David S. P. Tan, Singapore  
Michele Teng, Australia  
Han Chong Toh, Singapore

---

## LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

---

## ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to [esmo.org](http://esmo.org).

---

## ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



**Bristol-Myers Squibb**



**MSD**



---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Luigi Taddei 4  
6962 Lugano - Viganello  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Monday, 20 November 2017

<b>09:00-09:15</b> 15'	<b>Introduction</b>	
15'	Historical introduction	John B.A.G. Haanen, NL Ross A. Soo, SG
<b>09:15-09:55</b> 40'	<b>SESSION 1</b> <b>History of cancer immunology / immunotherapy</b>	
30'	Where do we come from (an historical retrospective from more than a century ago up the IL2, alfa-interferon times, including LAKC, TILs and vaccines and the reason for failure)	John B.A.G. Haanen, NL
10'	Discussion	Faculty
<b>09:55-10:50</b> 55'	<b>SESSION 2</b> <b>Principles of tumour immunology</b>	
45'	<ul style="list-style-type: none"> <li>- The concept of Tumour-Associated Antigens (TAA)</li> <li>- Cellular and humoral response to TAAs</li> <li>- The concept of immunosurveillance and the role of innate immunity</li> <li>- Immune balance against cancer</li> </ul>	Michele Teng, AU
10'	Discussion	Faculty
<b>10:50-11:20</b>	<b>Coffee break</b>	
<b>11:20-11:45</b> 25'	<b>SESSION 3</b> <b>Recent advances in tumour immunology</b>	
15'	The role of Immune Check Points in immunosuppression and mechanisms of actions of Immune Check Point Inhibitors ICPI (CTLA-4 and PD-1/PD-L1 axis)	Han Chong Toh, SG
10'	Discussion	Faculty
<b>11:45-14:45</b> 120'	<b>SESSION 4</b> <b>Recent advances with ICPI: Results in approved indication</b>	
20'	Melanoma advanced and adjuvant	John B.A.G. Haanen, NL
25'	Advanced Non-Small-Cell Lung Cancer	Ross A. Soo, SG
15'	Discussion	Faculty
<b>12:45-13:45</b>	<b>Lunch</b>	
20'	Advanced urinary cancer (renal and bladder)	Ravindran Kanesvaran, SG
15'	Head and neck cancer	Anthony Tak Cheung Chan, HK
10'	Merkel cell carcinoma	John B.A.G. Haanen, NL
15'	Discussion	Faculty
<b>14:45-15:00</b> 15'	<b>SESSION 5</b> <b>Issues related to ICPI in practice - part 1</b>	
15'	ESMO Magnitude of Clinical Benefit Score for ICPI	Solange Peters, CH
<b>15:00-15:30</b>	<b>Coffee break</b>	

<b>15:30-17:00</b> 90'	<b>SESSION 6</b> <b>Present development with ICPI: Non-approved indication</b>	
20'	Gastro-intestinal cancers (colorectal, HCC, gastric, anal canal)	Su Pin Choo, SG
15'	Gynaecological tumours (breast and ovaries)	David S. P. Tan, SG
20'	Glioblastoma	Matthias Preusser, AT
20'	Haematological malignancies (including Hodgkin's disease)	Soon Thye Lim, SG
15'	Discussion	Faculty
<b>19:45</b>	<b>Dinner</b>	

## Tuesday, 21 November 2017

<b>08:30-09:45</b> 75'	<b>SESSION 7</b> <b>Issues related to ICPI in practice - part 2</b>	
20'	Selection of patients with predictive biomarkers: The issue of PD-1/PD-L1	Teh-Ying Chou, TW
20'	Assessment of efficacy and Immune-Related RECIST Criteria	Kenneth John O'Byrne, AU
20'	Immune related toxicities and management	Kenneth John O'Byrne, AU
15'	Discussion	Faculty
<b>09:45-10:25</b> 40'	<b>SESSION 8</b> <b>Audience cases</b>	
4x10'	4 x Participants clinical case discussion	Faculty

Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion

<b>10:25-10:55</b>	<b>Coffee break</b>	
<b>10:55-12:10</b> 75'	<b>SESSION 9</b> <b>Further possible approaches in cancer immunotherapy</b>	
35'	- Identification of new antigens - Vaccines: Reasons for past failures and future development	Han Chong Toh, SG
25'	- Other Check Point Inhibitors - Combined approach including radiation, chemotherapy and targeted agents	Ross A. Soo, SG
15'	Discussion	Faculty
<b>12:10-12:25</b> 15'	<b>SESSION 10</b> <b>Round table discussion</b>	
<b>12:25-12:35</b> 10'	<b>SESSION 11</b> <b>Closure and farewell</b>	
<b>12:35-13:35</b>	<b>Lunch</b>	